3'-Azido-3'-deoxythymidine β-D-glucuronide (sodium salt) (Synonyms: AZT glucuronide,Zidovudine glucuronide) |
| Catalog No.GC10387 |
Zidovudine O-β-D-glucuronide (3'-Azido-3'-deoxythymidine β-D-glucuronide) sodium is the major metabolite of Zidovudine.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 133525-01-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
3'-Azido-3'-deoxythymidine β-D-glucuronide is the metabolite of zidovudine, a nucleoside reverse transcriptase inhibitor.
Zidovudine, an antiretroviral medication used to prevent and treat HIV, is recommended for use with other antiretroviral and may be also used to prevent mother to child spread during birth or after a needlestick injury or other potential exposure.
In vitro: 3'-Azido-3'-deoxythymidine β-D-glucuronide is a metabolite of zidovudine, formed by direct conjugation by UDP-glucuronosyltransferase 2B7. The azido group of both zidovudine and 3'-azido-3'-deoxythymidine β-D-glucuronide could be reduced to an amino group by cytochrome CYP3A, CYP2A6, or CYP2B1, forming 3’-amino-3’-deoxythymidine (AMT) and AMT glucuronide, respectively [1].
In vivo: Animal study found that zidovudine-treated rats had higher systolic blood pressure, greater heart weight and greater interventricular septum thickness. Electron microscopy revealed mitochondrial swelling in myocardiocytes in zidovudine-treated rats. Reduced response to contractile stimuli and enhanced relaxation in response to charbacol were observed in the aortic rings of zidovudine-treated rats. The aortic myocytes of zidovudine-treated rats contained apparently unaffected ultrastructural features, but light microscopy suggested their marked enlargement [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Walsky, R. L.,Bauman, J.N.,Bourcier, K., et al. Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors. Drug Metabolism and Disposition 40(5), 1051-1065 (2012).
[2] Ruga E, Bova S, Nussdorfer G, Mazzocchi G, Rebuffat P, Milanesi O, Cargnelli G. Zidovudine-induced alterations in the heart and vascular smooth muscle of the rat. Cardiovasc Res. 2003 Oct 15;60(1):147-55.
| Cas No. | 133525-01-6 | SDF | |
| Synonyms | AZT glucuronide,Zidovudine glucuronide | ||
| Chemical Name | 3'-azido-3'-deoxy-5'-O-β-D-glucopyranuronosyl-thymidine, monosodium salt | ||
| Canonical SMILES | O=C([O-])[C@@H](O1)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC[C@@H]2[C@@H](N=[N+]=[N-])C[C@H](N3C=C(C)C(NC3=O)=O)O2.[Na+] | ||
| Formula | C16H20N5O10 • Na | M.Wt | 465.4 |
| Solubility | ≤0.5mg/ml in DMSO | Storage | Store at 2-8°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.1487 mL | 10.7434 mL | 21.4869 mL |
| 5 mM | 0.4297 mL | 2.1487 mL | 4.2974 mL |
| 10 mM | 0.2149 mL | 1.0743 mL | 2.1487 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 3 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *